Video Experimental Relacionado
Updated: Feb 19, 2026

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma
Published on: April 15, 2022
La evolución al mieloma hepta-refractario implica la pérdida secuencial de CD38, BCMA y GPRC5D
C Riedhammer1, M Truger2, H Lee3
1Department of Internal Medicine 2, University Hospital of Würzburg, Würzburg, Germany.
El mieloma múltiple hepta-refractario (MM) es una nueva enfermedad en etapa terminal con mala supervivencia. La complejidad genómica y la pérdida de antígenos, incluido el BCMA, impulsan la resistencia y exigen diagnósticos avanzados y terapias novedosas.
Más Videos Relacionados
08:31Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
Videos de Conceptos Relacionados
Treatment Resistant Cancers
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...